Valsartan/hydrochlorothiazide: A review of its pharmacology, therapeutic efficacy and place in the management of hypertension

Drugs

Volumn 62, Issue 13, 2002, Pages 1983-2005

  Wellington, Keri ^a   Faulds, Diana M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Angiotensin II receptor antagonist; Blood pressure; Hydrochlorothiazide; Hypertension; Pharmacodynamics; Pharmacokinetics; Therapeutic use; Valsartan

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENAZEPRIL; HYDROCHLOROTHIAZIDE; THIAZIDE DIURETIC AGENT; VALSARTAN;

ANGIONEUROTIC EDEMA; ANURIA; AREA UNDER THE CURVE; BIOEQUIVALENCE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG TOLERANCE; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; HYPOKALEMIA; LEG EDEMA; MONOTHERAPY; NONHUMAN; ORTHOSTATIC HYPOTENSION; RAT; REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VERTIGO;

EID: 0036384291     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262130-00015     Document Type: Review

References (69)

1. Beevers G, Lip GYH, O'Brien E. ABC of hypertension: the pathophysiology of hypertension. BMJ 2001 Apr 14; 322 (7291): 912-6
2. Kaplan NM. Guidelines for the management of hypertension. Can J Cardiol 2000; 16: 1147-52
3. Alderman M, Arakawa K, Beilin L, et al. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Blood Press 1999; 8 (Suppl. 1): 9-43
4. Kendall MJ. Better beta blockade and optimal antihypertensive therapy. Br J Cardiol 2000; 7: 323-7
5. McInnes GT. Systolic hypertension as a cardiovascular risk factor. Blood Press 2002; 11 (3): 134-43
6. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee. The sixth report of the Joint National Committee on Prevention, Detection. Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997 Nov 24; 157: 2413-46
7. Ramsay LE, Williams B, Johnston GD. et al. British Hypertension Society guidelines for hypertension management 1999: summary. Br Med J 1999 Sep 4; 319: 630-5
8. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2002 Jan; 25 (1): 199-201
9. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998 Jun 13; 351 (9118): 1755-62
10. Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997 Aug; 54 (2): 299-311
11. Pickkers P, Hughes AD, Russel FGM, et al. Thiazide-induced vasodilation in humans is mediated by potassium channel activation. Hypertension 1998 Dec; 32: 1071-6
12. Langtry HD, McClellan KJ. Valsartardhydrochlorothiazide. Drugs 1999 May; 57 (5): 751-5; discussion 756-8
13. U.S. Pharmacopeia. USP dictionary of USAN and international drug names. 2001 ed. Rockville (MD): United States Pharmacopeial Convention, Inc., 2001
14. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000 Feb 19; 355 (9204): 637-45
15. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996 Jun 20; 334 (25): 1649-54
16. Unger T. Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different? Am J Cardiol 1999 Nov 18; 84 (10A): 9S-15S
17. 1-receptor subtype. Br J Pharmacol 1993 Oct; 110 (2): 761-71
18. 1 receptors. Regul Pept 1995 Nov 10; 59 (3): 303-11
19. Criscione L, Bradley WA, Bühlmayer P, et al. Valsartan: preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 1995; 13 (3): 230-50
20. Verheijen I, Fierens FLP, DeBacker JP, et al. Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type I receptors. Fundam Clin Pharmacol 2000; 14 (6): 577-85
21. Latif F, Tandon S, Obeleniene R, et al. Angiotensin II type 1 receptor blockade with 80 and 160 mg valsartan in healthy, normotensive subjects. J Card Fail 2001 Sep; 7 (3): 265-8
22. Mueck AO, Seeger H, Heuberger W, et al. Comparison of valsartan with candesartan on their possible protection from atherosclerosis. Journal of Clinical and Basic Cardiology 2001; 4 (4): 297-9
23. Mueck AO, Seeger H, Lippert TH. Valsartan inhibits angiotensin II-stimulated proliferation of smooth muscle cells from human coronary artery. Int J Clin Pharmacol Ther 1999 Jul; 37: 365-6
24. Hayashi N, Yamamoto S, Kometani M, et al. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist: 3rd communication: hemodynamic effects of valsartan in rats and dogs. Arzneimittelforschung Drug Res 1997 May; 47: 620-5
25. Yamamoto S, Hayashi N, Kometani M, et al. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist: 1st communication: antihypertensive effects of valsartan in hypertensive models. Arzneimittelforschung Drug Res 1997 May; 47: 604-12
26. Hanefeld M, Abletshauser C. Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension. J Int Med Res 2001 Jul-2001 31; 29: 270-9
27. Plum J, Bunten B, Nemeth R, et al. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol 1998 Dec; 9: 2223-34
28. Thürmann PA, Kenedi P, Schmidt A, et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998 Nov 10; 98 (19): 2037-42
29. Viberti G, Wheeldon NM. for the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002 Aug 6; 106 (6): 672-8
30. Jackson EK. Diuretics. Hardman JG, Limbird LE. The pharmacological basis of therapeutics. 10th ed. US: McGraw Hill, 2001: 757-88
31. Pickkers P, Garcha RS, Schachter M, et al. Inhibition of carbonic anhydrase accounts for the direct vascular effects of hydrochlorothiazide. Hypertension 1999 Apr; 33 (4): 1043-8
32. van Brummelen P, Man in't Veld AJ, Schalekamp MA. Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders. Clin Pharmacol Ther 1980 Mar; 27 (3): 328-36
33. Webb RL, Navarrete AE, Davis S. Effects of valsartan and hydrochlorothiazide alone and in combination on blood pressure and heart rate in conscious-telemetered spontaneously hypertensive rats (SHR). Am J Hypertens 1998 Jan; 11 (1 Pt 1): 59-65
34. Flesch G, Müller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol 1997; 52 (2): 115-20
35. Müller P, Flesch G, de Gasparo M, et al. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. Eur J Clin Pharmacol 1997; 52 (6): 441-9
36. Colussi DM, Parisot C, Rossolino ML, et al. Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist. J Clin Pharmacol 1997 Mar; 37 (3): 214-21
37. Kalbag J, Prasad P, Redalieu E, et al. Plasma concentrations and antihypertensive effect of 10 to 160 mg dosea of valsartan (VAL) in hypertensive patients [abstract no. PPDM 8140]. Pharm Res 1994; 11 (10 Suppl.): S367
38. Taeschner W, Vozeh S. Appendix A: Pharmacokineic drug data. Speight TM, Holford NHG. Avery's Drug Treatment. 4th ed. Auckland, New Zealand: Adis International Limited, 1997: 1629-64
39. 14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica 1997 Jan; 27 (1): 59-71
40. Sioufi A, Marfil F, Jaouen A, et al. The effect of age on the pharmacokinetics of valsartan. Biopharm Drug Dispos 1998 May; 19: 237-44
41. Prasad P, Mangat S, Choi L, et al. Effect of renal function on the pharmacokinetics of valsartan. Clin Pharmacokinet 1997; 13 (4): 207-14
42. Leidig MF, Delles C, Kuchenbecker C, et al. Pharmacokinetics of valsartan in hypertensive patients on long-term haemodialysis. Clin Drug Invest 2001; 21 (1): 59-66
43. Brookman LJ, Rolan PE, Benjamin IS, et al. Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther 1997 Sep; 62 (3): 272-8
44. Novartis. Diovan HCT prescribing information [online]. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/diovan_hct.pdf [Accessed 2002 Jul 1]
45. Close P. Expert report on the clinical documentation. Co-Diovan™ 80/12.5 mg film-coated tablets (valsartan/hydrochlorothiazide, CGP 63170). Novartis Pharma AG, Basel, Switzerland, 1997
46. Benz JR, Black HR, Graft A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998 Dec; 12(12): 861-6
47. Schmidt A, Adam SA, Kolloch R, et al. Antihypertensive effects of valsartan/hydrochlorothiazide combination in essential hypertension. Blood Press 2001; 10 (4): 230-7
48. Hall WD, Montoro R, Littlejohn T, et al. Efficacy and tolerability of valsartan in combination with hydrochlorothiazide in essential hypertension. Clin Drug Invest 1998 Sep; 16 (3): 203-10
49. Palatini P, Malacco E, Fogari R, et al. A multicenter, randomized double-blind study of valsartan/hydrochlorothiazide combination versus amlodipine in patients with mild to moderate hypertension. J Hypertens 2001 Sep; 19 (9): 1691-6
50. Waeber B, Aschwanden R, Sadecky L, et al. Combination of hydrochlorothiazide or benazepriI with valsartan in hypertensive patients unresponsive to valsartan alone. J Hypertens 2001 Nov; 19 (11): 2097-104
51. Scholze J, Probst G, Bertsch K. Valsartan alone and in combination with hydrochlorothiazide in general practice: results from two postmarketing surveillance studies involving 54 928 patients with essential hypertension. Clin Drug Invest 2000 Jul; 20 (1): 1-7
52. Hall J, Marbury T, Gray J, et al. Long term safety, tolerbility and efficacy of valsartan: results from one and two year trials. J Drug Assess 1998; 1: 281-93
53. Chrysant SG, Wombolt DG, Feliciano N, et al. Long-term efficacy, safety, and tolerability of valsartan and hydrochlorothiazide in patients with essential hypertension. Curr Ther Res 1998 Nov; 59 (11): 762-72
54. Oparil S, Dyke S, Harris F. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996; 18 (5): 797-810
55. Palatini P, Malacco E, Di Somma S, et al. Trough:peak ratio and smoothness index in the evaluation of 24-h blood pressure control in hypertension: a comparative study between valsartan/hydrochlorothiazide combination and amlodipine. Eur J Clin Pharmacol 2002 Jan; 57 (11): 765-70
56. Benz J, Oshrain C, Henry D, et al. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997 Feb; 37 (2): 101-7
57. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38
58. Howes LG, Tran D. Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema? Drug Saf 2002; 25 (2): 73-6
59. Agarwal R. Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 2001 Jun; 59 (6): 2282-9
60. Ruilope L. Improving prognosis in hypertension: exploring the benefits of angiotensin II type 1 receptor blockade. Blood Press Suppl. 2000; 1: 31-5
61. Pedrinelli R, Dell'Omo G, Mariani M. Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension. J Hum Hypertens 2001; 15 (7): 455-61
62. Mann J, Julius S. for the Value Trial Group. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial of Cardiovascular Events in Hypertension. Rationale and Design. Blood Press 1998; 7: 176-83
63. Kjeldsen SE, Julius S, Brunner H, et al. for the VALUE Trial Group. Characteristics of 15314 hypertensive patients at high coronary risk. The VALUE trial. Blood Press 2001; 10: 83-91
64. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345 (23): 1667-75
65. Wellington K, Goa KL. Valsartan: in chronic heart failure. Am J Cardiovasc Drug 2002; 2 (4): In press
66. Kahan T. The importance of left ventricular hypertrophy in human hypertension. J Hypertens 1998; 16 (Suppl. 7): S23-9
67. Korner PI, Jennings GL. Assessment of prevalence of left ventricular hypertrophy in hypertension. J Hypertens 1998; 16 (6): 715-23
68. Schunkert H, Sadoshima J, Cornelius T, et al. Angiotensin II-induced growth responses in isolated adult rat hearts. Evidence for load-independent induction of cardiac protein synthesis by angiotensin II. Circ Res 1995 Mar; 76 (3): 489-97
69. Schunkert H, Hense H-W, Muscholl M, et al. Associations between circulating components of the renin-angiotensin- aldosterone system and left ventricular mass. Heart 1997 Jan; 77 (1): 24-31